Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

MeDiApp-PCOS: A Mobile Mediterranean Diet App for Women With Polycystic Ovary Syndrome (MeDiApp-PCOS)

31. maj 2026 opdateret af: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Randomized Controlled Trial of a Mobile Application With Personalized Mediterranean Diet-Based Recommendations in Women With Polycystic Ovary Syndrome

This randomized clinical trial will test whether a mobile application with personalized Mediterranean diet-based recommendations can improve health outcomes in women with polycystic ovary syndrome compared with standard lifestyle advice.

Participants will be assigned to either the mobile application group or the standard lifestyle advice group.

The primary outcomes are change in LDL cholesterol and change in body mass index after 3 months.

Secondary outcomes include changes in metabolic and hormonal measures, quality of life, treatment adherence, and ovulatory function assessed through 6 months.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Female participants aged 18 to 45 years.
  • Diagnosis of polycystic ovary syndrome (PCOS) with an anovulatory phenotype according to the Rotterdam criteria (2003).

  • Oligo-ovulation or anovulation, defined as menstrual cycle length greater than 35 days or fewer than 8 menstrual periods per year, together with at least one of the following:

    • Clinical and/or biochemical hyperandrogenism.
    • Polycystic ovarian morphology on ultrasound, defined as at least 20 follicles measuring 2 to 9 mm in either ovary and/or ovarian volume of at least 10 cm3.
  • Possession of a smartphone compatible with the study application (Android or iOS).
  • Ability and willingness to use the mobile application and comply with study procedures.
  • Provision of written informed consent before any study-specific procedures are performed.

Exclusion Criteria:

  • Pregnancy or breastfeeding at the time of enrollment.
  • Planning pregnancy during the study period.
  • Type 1 or type 2 diabetes mellitus.
  • Other endocrine disorders that may affect reproductive or metabolic function, including Cushing syndrome, congenital adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, or uncontrolled thyroid disease.
  • Severe liver disease, including cirrhosis or liver failure.
  • Severe renal impairment, defined as estimated glomerular filtration rate less than 30 mL/min/1.73 m2.
  • Severe cardiovascular disease, including unstable angina, myocardial infarction within the previous 6 months, or stroke within the previous 6 months.
  • Use within the previous 3 months of medications that may affect body weight, carbohydrate metabolism, androgen status, or reproductive function, including metformin, oral contraceptives, antiandrogens, gonadotropin-releasing hormone agonists or antagonists, clomiphene citrate, glucocorticoids, thiazolidinediones, or weight-loss drugs.
  • Current or past eating disorders, including anorexia nervosa, bulimia nervosa, or binge eating disorder.
  • Mental disorders or cognitive conditions that, in the opinion of the investigator, would preclude safe participation or compliance with study procedures.
  • Participation in another clinical trial within the previous 3 months.
  • Refusal or inability to provide written informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Mobile Application With Personalized Mediterranean Diet-Based Recommendations

Participants randomized to this arm will receive access to a mobile application specifically developed for women with polycystic ovary syndrome.

The application provides personalized dietary recommendations based on the Mediterranean diet, a system for tracking food intake and physical activity, automated feedback and motivational messages, weekly progress reports, and educational materials on PCOS and healthy lifestyle.

Participants will be instructed to use the application daily for 6 months, including completion of nutrition and activity diaries and review of recommendations and feedback.
Adfærdsmæssigt: Mobile Application-Based Personalized Mediterranean Diet and Lifestyle Intervention

The intervention consists of a mobile application providing personalized Mediterranean diet-based nutrition plans, a food database with nutritional information, automatic calculation of caloric intake and macronutrient composition, monitoring of adherence to the Mediterranean diet, physical activity recommendations (including minimum weekly minutes of moderate aerobic activity and strength training), an activity diary with step tracking, automated feedback and motivational messages, weekly progress reports, push notifications with reminders, and educational materials on PCOS and healthy lifestyle.

Participants are instructed to use the application daily for 6 months, to enter food intake and physical activity, and to review personalized feedback. The intervention aims to optimize dietary habits, increase physical activity, improve metabolic parameters, and support restoration of ovulatory function in women with PCOS.
Aktiv komparator: Standard Lifestyle Advice

Participants randomized to this arm will receive standard written recommendations for lifestyle modification in polycystic ovary syndrome, including principles of the Mediterranean diet, recommended foods and example menus, and physical activity recommendations.

They will receive a one-time consultation with a dietitian at baseline with explanation of the recommendations and will be advised to keep a paper diary of nutrition and physical activity during the follow-up period.

No access to the mobile application will be provided in this arm.
Adfærdsmæssigt: Standard Lifestyle Advice for PCOS

Standard care consisting of written lifestyle recommendations for women with polycystic ovary syndrome.

This includes printed materials describing the Mediterranean diet (principles, recommended and discouraged foods, example menus), physical activity recommendations, and general educational information on PCOS and the importance of lifestyle changes.

Participants will receive a one-time dietitian consultation at baseline to review the recommendations and will be advised to keep a paper diary of nutrition and physical activity throughout the follow-up period. No digital application or additional feedback system will be provided.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in LDL cholesterol from baseline to 3 months
Tidsramme: Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Serum low-density lipoprotein (LDL) cholesterol concentration measured in mmol/L after an overnight fast
Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Change in body mass index (BMI) from baseline to 3 months
Tidsramme: Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Body mass index calculated as weight (kg) divided by height (m²)
Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in fasting insulin and HOMA-IR from baseline to 3 months
Tidsramme: Baseline (Visit 1) and Month 3 (Visit 2)

Fasting serum insulin (μIU/mL) and insulin resistance assessed by HOMA-IR index, calculated as (fasting glucose × fasting insulin) / 22.5.

Changes will be calculated as values at 3 months (Visit 2) minus baseline values (Visit 1)
Baseline (Visit 1) and Month 3 (Visit 2)
Change in triglycerides and HDL cholesterol from baseline to 3 months
Tidsramme: Baseline (Visit 1) and Month 3 (Visit 2)

Fasting serum triglycerides and high-density lipoprotein (HDL) cholesterol measured using standard enzymatic methods.

Changes will be calculated as values at 3 months (Visit 2) minus baseline (Visit 1).
Baseline (Visit 1) and Month 3 (Visit 2)
Proportion of participants achieving at least 5% weight loss at 3 months
Tidsramme: Baseline (Visit 1) and Month 3 (Visit 2)

Percentage of participants with a reduction in body weight of ≥5% from baseline to 3 months.

Weight is measured in light clothing without shoes. Proportion will be compared between groups using chi-square or Fisher's exact test.
Baseline (Visit 1) and Month 3 (Visit 2)
Restoration of regular menstrual cycles during 3-6 months
Tidsramme: From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)

Proportion of participants who achieve regular menstrual cycles, defined as cycle length 21-35 days, during the period between Month 3 and Month 6 of follow-up.

Information will be collected from menstrual calendars reviewed at Visit 3.
From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)
Frequency of ovulatory cycles during 3-6 months
Tidsramme: From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)

Number and proportion of ovulatory cycles per participant during the period from Month 3 to Month 6.

Ovulation will be confirmed by serum progesterone >5 ng/mL on cycle days 21-23 and/or by ultrasound follicle monitoring when indicated.
From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)
Adherence to mobile application use at 3 months (main group only)
Tidsramme: From Day 0 to Month 3
Adherence will be assessed as the percentage of days with completed nutrition diaries and the mean Mediterranean diet adherence score calculated automatically by the mobile application over the 3 month period.
From Day 0 to Month 3
Serum total testosterone, free androgen index (calculated), androstenedione and sex hormone-binding globulin (SHBG) measured by immunochemiluminescence assays. Changes will be calculated as 3 month values minus baseline values.
Tidsramme: Baseline (Visit 1) and Month 3 (Visit 2)

Serum total testosterone, free androgen index (calculated), androstenedione and sex hormone-binding globulin (SHBG) measured by immunochemiluminescence assays.

Changes will be calculated as 3 month values minus baseline values.
Baseline (Visit 1) and Month 3 (Visit 2)
Change in inflammatory markers: IL-5, Il-22, IL-1 RA,MCP-1, CCL-7 from baseline to 3 months
Tidsramme: Baseline (Visit 1) and Month 3 (Visit 2)
Inflammatory markers measured using standard assays. Changes are defined as 3 month values minus baseline values.
Baseline (Visit 1) and Month 3 (Visit 2)
Change in Mediterranean diet adherence score (15-Items Pyramid based Mediterranean Diet Score (PyrMDS)) from baseline to 3 months
Tidsramme: Baseline (Visit 1) and Month 3 (Visit 2)

Final score: 0-15

  • 0-5 points - Low adherence to the Mediterranean diet
  • 6-9 points - Moderate adherence to the Mediterranean diet
  • 10-12 points - Good adherence to the Mediterranean diet
  • 13-15 points - High adherence to the Mediterranean diet
Baseline (Visit 1) and Month 3 (Visit 2)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

13. maj 2026

Primær færdiggørelse (Anslået)

30. december 2028

Studieafslutning (Anslået)

30. juni 2029

Datoer for studieregistrering

Først indsendt

13. maj 2026

Først indsendt, der opfyldte QC-kriterier

13. maj 2026

Først opslået (Faktiske)

20. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

31. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 125042105343-8

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med PCOS (polycystisk ovariesyndrom)

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Venezuela

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner